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SUMMARY
 
HIV-associated immune reconstitution disease (IRD) is the
clinical presentation or deterioration of opportunistic infections
that results from enhancement of pathogen-speciﬁc immune
responses among patients responding to antiretroviral treatment
(ART). The vast majority of reported cases of IRD have been
associated with mycobacterial, chronic viral and invasive fungal
infections; such cases result from dysregulated augmentation of
cell-mediated type 1 cytokine-secreting host immune responses.
However, the spectrum of infections now recognized as associated
with IRD is expanding and includes a number of parasitic
infections, which may be mediated by different immunopatholog-
ical mechanisms. These include leishmaniasis (visceral, cutaneous,
mucosal and post kala azar dermal leishmaniasis), schisto-
somiasis and strongyloidiasis. Since the major burden of HIV
lies in resource-limited countries where access to ART is now
rapidly expanding, increased awareness and knowledge of these
phenomena is important. Here we review the clinical spectrum
and pathogenesis of IRD associated with parasitic infections.
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INTRODUCTION
 
HIV-associated morbidity and mortality has dramatically
decreased in many high-income countries since the advent of
antiretroviral treatment (ART) in the mid 1990s (1–3). Robust
suppression of viral replication by ART permits both quan-
titative and functional reconstitution of the immune system
(4–6). As a result, primary and secondary prophylaxis for
many opportunistic infections that occur among those with
advanced immunodeﬁciency can often be discontinued (7).
However, the initial rapid phase of immune recovery may
also directly result in adverse clinical phenomena. Previously
subclinical infections may be ‘unmasked’ or pre-existing
partially treated opportunistic infections may clinically dete-
riorate (8–10). Such phenomena are believed to arise from a
dysregulated augmentation of the host inﬂammatory response
to these infections. Various terms have been used to refer to
this, including ‘immune reconstitution syndrome’, ‘immune
restoration disease’, and the ‘immune reconstitution
inﬂammatory syndrome’ (familiarly abbreviated to ‘IRIS’).
In this review we have used the term ‘immune reconstitution
disease’ (IRD).
IRD is not a new phenomenon, but has long been recog-
nized as a complication occurring among patients with severe
immunosuppression in whom immune function is rapidly
restored. Thus, for example, IRD may occur following with-
drawal or rapid dosage reduction of corticosteroid treatment
and among patients in whom the blood neutrophil count
recovers following cytotoxic chemotherapy or bone marrow
transplantation (11). The pathogens involved in IRD reﬂect
the spectrum of opportunistic infections associated with the
speciﬁc form of immunosuppression. For example, IRD
following recovery from neutropenia is typically associated
with fungal and pyogenic infections (11).
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The vast majority of cases of IRD associated with ART
have been reported from high-income countries and have been
associated with a wide range of non-parasitic opportunistic
infections, including: (a) bacteria (
 
Mycobacterium tuberculosis
 
,
 
Mycobacterium avium
 
 complex and other non-tuberculous
mycobacteria); (b) viruses (cytomegalovirus, varicella zoster
virus, herpes simplex virus, human herpes virus-8, hepatitis
B and C and JC virus); and (c) fungi (
 
Pneumocystis jirovecii
 
,
 
Cryptococcus neoformans and Histoplasma
 
  spp.) (8–10).
However, the spectrum of infections recognized to be associ-
ated with IRD continues to increase and case reports now
describe IRD associated with some parasitic infections
(
 
vide infra
 
).
The majority of people with HIV/AIDS live in resource-
limited countries and in June 2005 WHO estimated that 6·5
million people living in such countries were in urgent need
of ART (12). Despite formidable logistical challenges, access
to ART is now expanding. However, patients in resource-
limited settings typically enter ART programmes with advanced
symptomatic disease and very low blood CD4 cell counts
(13,14). This predisposes them to high rates of both clinical
and subclinical opportunistic infections that may potentially
be associated with IRD. To date, IRD associated with
tuberculosis and cryptococcocal meningitis is reported to be
associated with the greatest burden of morbidity and mortality
in sub-Saharan Africa (13,15). However, the prevalence of
chronic parasitic infections is very high in these populations
and yet very little is known about whether these infections
may either be associated with IRD or may perhaps modulate
immune responses involved in IRD associated with other
pathogens. In this paper we review what is currently known
about the clinical manifestations and pathogenesis of IRD
associated with parasitic infections.
 
DEFINITION OF IRD
 
IRD can be deﬁned as the clinical presentation or deteriora-
tion of opportunistic infections that results from enhancement
of pathogen-speciﬁc immune responses among patients
responding to ART. However, diagnosis in practice is not
straightforward, being one of clinical judgement based on
various lines of indirect evidence. These may include: (a) the
clinical manifestation or pattern of progression of an oppor-
tunistic infection that is unusual; (b) a temporal relationship
with ART initiation; (c) exclusion of alternative explanations;
(d) demonstrated efﬁcacy of ART (e.g. reduction in viral load
or rise in CD4 cell count; (e) evidence of improved CD4
cell function (e.g. development of a positive tuberculin skin
test); and (f ) histopathology consistent with the diagnosis.
Competing explanations for these clinical manifestations
that should be excluded are the occurrence of opportunistic
infections as a result of residual immunodeﬁciency and
inadequate treatment of an opportunistic infection, including
that resulting from drug resistance.
 
IMMUNOLOGICAL EFFECTS OF ART
 
Successful ART is associated with a rapid (> 90%) reduction
in plasma viral load within the ﬁrst weeks of ART. The most
characteristic immunological feature of HIV infection is deple-
tion of CD4 T cell numbers, and restoration of the CD4 cell
subset during ART appears to occur in two principal phases.
The initial rapid phase of CD4 cell recovery can usually be
detected within the ﬁrst 1–2 weeks of starting treatment and
extends over 2–3 months (4,5). Data suggest that this phase
largely represents a redistribution of activated CD4
 
+
 
CD45RO
 
+
 
memory cells previously sequestered in lymphoid tissue and
a reduction in apoptotic cell death (4,5,16,17). Those with the
greatest pretreatment viral loads and CD4 decline have the
greatest rates of phase 1 CD4 cell count recovery (18–21). A
slower second phase of CD4 cell expansion persists for 1–
2 years with variable smaller increments occurring thereafter.
This second thymus-dependent phase is associated with
expansion of naïve CD45RA
 
+
 
CD62L
 
+
 
 cells (4,22).
The increase in circulating CD4 cell numbers is also asso-
ciated with an improvement in effector function, the extent
of which is directly related to the degree of viral load
suppression and the CD4 cell counts in the longer term (6).
IL-2-mediated T lymphocyte proliferative responses to recall
antigens are restored (23,24). A switch from type 2 to type
1 cytokine proﬁles in T lymphocyte stimulation assays and
in tissues is detectable early in treatment, with increases in
IFN-
 
γ
 
 and IL-2 production in response to antigen (25,26).
There is diversiﬁcation of the pathogen-speciﬁc T cell receptor
repertoire (27,28) and delayed-type hypersensitivity responses
to antigens assessed by skin testing are restored (24,29).
Although HIV is principally characterized by CD4 cell
depletion, functional deﬁcits in other cells of the innate and
acquired immune systems also occur. However, the literature
concerning effects of ART on other cell types is much less
comprehensive than that concerning CD4 cell reconstitution.
Moreover, many of these effects are CD4 cell-dependent, so that
attributing ART-induced improvements in immune function
to either CD4 cells or to other cell types is difﬁcult.
Decreased macrophage function, including impaired
chemotaxis, binding of microorganisms, phagocytosis, anti-
gen processing, microbicidal activity and capacity to secrete
interleukin-12 is recognized (30–34). However, data on the
impact of ART on these functions are lacking. Dendritic
cells (DC) in their role as antigen-presenting cells exert a
substantial inﬂuence on the phenotype of the subsequent
acquired immune response. Both plasmacytoid (pDC) and
myeloid (mDC) subsets are reduced in numbers in HIV
infection. During ART there is evidence that the defect in 
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pDC is only partially reversible (35,36), whereas the mDC
subset appears better reconstituted by ART (35–37). This
differential recovery is of interest when considering IRD
because the mDC subset is responsible for polarizing acquired
response towards type 1 responses. Reduced CD4
 
+
 
 T cell
counts are also associated with decreased circulating CD3
 
–
 
/
CD16
 
+
 
/CD56
 
+
 
 NK cells (38), however, ART does not appear
to be associated with an increase in NK cell function (38–41).
CD8 activation (as determined by co-expression of CD38
and HLA-DR) decreases during ART (4,16,22), probably
reﬂecting to a large extent the reduction in HIV-speciﬁc CD8
response that accompanies the reduction in antigen load (42).
However, CD8-mediated responses to CMV, for example,
improve in the context of an expanding T cell repertoire (28),
an effect which appears CD4 cell dependent (43).
The apparent marked dysregulation of the immune
response that characterizes IRD suggests that T regulatory
cell function may be an important factor in the development
of IRD. An inhibitory effect on the ability of DC to mature
from peripheral monocytes has been attributed to the presence
of HIV-induced CD4
 
+
 
 CD25
 
+
 
 IL-10-secreting T regulatory
cells (44). In addition regulatory T cells are present at higher
frequency in the tonsillar tissue of untreated patients than
in tissue from those receiving ART (45). It is possible that
decreased T regulatory cell function during ART may enable
mDC to polarize the acquired immune response towards
type 1, thereby favouring development of IRD.
HIV infection is associated with polyclonal B cell activa-
tion and defective speciﬁc antibody responses (46) and ART
is associated with a reduction in risk of serious bacterial
infections (e.g. pneumococcal disease) in which immunity is
antibody-dependent (47). Furthermore, ART improves the
antibody response following vaccination or revaccination,
although restoration is not always complete (48,49). There
is very little information, however, about the effect of ART
on eosinophil numbers and on either speciﬁc or total IgE
responses that may be relevant to development of IRD in
association with helminth infections.
 
IMMUNOLOGICAL MECHANISMS OF IRD
 
IRD is most likely to develop in association with those infec-
tions for which immune responses are markedly suppressed
by HIV and rapidly restored during ART. It occurs most frequ-
ently among patients with nadir CD4 cell counts < 50 cells/
 
µ
 
L (8,10) who frequently have either subclinical infections or
suppressed responses to clinical disease and yet also retain
capacity for rapid increments in immune function (21). IRD
results from exaggerated host inﬂammatory responses to
soluble antigen, live organisms (in the case of subclinical or
partially treated infections) or dead organisms (in the case
of treated infections) (8,10,15). It is also recognized that
antigen may persist on DC for long periods, a phenomenon
recently demonstrated 
 
in vivo
 
 for HIV antigen despite success-
ful ART (50). When viable organisms are present, it may be
difﬁcult to distinguish between IRD and active opportunistic
infection, including that resulting from drug resistance. Whilst
antigen concentration is likely to inﬂuence the risk and
severity of IRD, this has not been formally studied.
The vast majority of cases of IRD develop in the ﬁrst
3 months of ART (8,10), corresponding to the ﬁrst phase of
immune reconstitution in which there is a very rapid increase
in both the number of circulating of CD45RO
 
+
 
 memory cells
as well as CD4 cell function (4). The extent of sequestration
of activated CD45RO
 
+
 
 memory cells in lymphoid tissue may
be directly related to the HIV load, which would explain
why those with the greatest pretreatment viral loads have
the greatest phase 1 rates of CD4 cell recovery during ART
(18,19) and the greatest risk of IRD (51,52). Recirculation
of this previously sequestered cell population may provide the
opportunity for relevant pathogen-speciﬁc cells to gain access
to sites of infection and engage in the host inﬂammatory
response to foreign antigen. IRD can develop within the ﬁrst
1–2 weeks of ART even prior to any detectable increase in
circulating CD4 cell numbers, and this is likely to reﬂect
rapid improvements in immune function.
Most cases of IRD are associated with chronic bacterial
infections, viral infections and deep fungal infections, which
typically trigger immunopathology via cell-mediated T-helper
type 1 (T
 
H
 
1) cytokine-secreting immune responses (8,10,53).
Much of our knowledge about the mechanisms of IRD comes
from study of cases of mycobacterial IRD (10). Development
of IRD coincides with restoration of T lymphocyte prolifer-
ative responses, IFN-
 
γ
 
 secretion and cell-mediated immune
responses to mycobacteria, leading to restoration of delayed
type hypersensitivity skin test responses to mycobacterial
antigens (29,54,55). These processes are associated with expan-
sion in the number of antigen-speciﬁc T cells during IRD
(53). Reports of hypercalcaemia (resulting from autologous
production of 1,25 dihydroxycholecalceriferol) as a manifes-
tation of mycobacterium-associated and cryptococcal IRD
also provide evidence of restoration of the physiological
function of granulomas (56,57). As might be expected, IRD
associated with viral infections, such as cytomegalovirus, JC
virus, varicella-zoster virus and hepatitis C virus, is associated
with restoration of CD8 T cell responses (58–61). However,
data regarding mechanisms of IRD associated with other
types of opportunistic infections are lacking.
What  determines whether a patient develops immune
responses that effectively clear infection vs. responses that lead
to the development of ﬂorid immunopathology is not clear.
It is perhaps the rapidity with which cell-mediated immune
responses are restored and a lack of compensating immuno-
regulatory mechanisms may lead to the uncontrolled 
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tissue-damaging responses that characterize IRD. In this
respect, it has been speculated that some patients may have
a genetically determined immunological predisposition to
development of IRD (62). It is hypothesized that polymor-
phisms in cytokine genes may inﬂuence the rate of clearance
of opportunistic pathogens or may cause dysregulation of the
inﬂammatory response. Association of such polymorphisms
with development of IRD has been described in small groups
of patients developing IRD associated with a range of organ-
isms (62). However, whether mechanistic relationships exist
has yet to be demonstrated.
 
IRD ASSOCIATED WITH PARASITIC 
INFECTIONS
 
The number of reports of IRD associated with parasitic
diseases is small but increasing (Table 1) and most have been
among immigrants to developed countries. Several reasons
may underlie this paucity of data. The association of parasitic
infections with IRD may be infrequent or may typically be
mild or non-speciﬁc, leading to lack of recognition. Indeed,
many parasitic infections such as schistosomiasis, trypano-
somiasis and ﬁlariasis have complex systems of immune
evasion, permitting these organisms to exist with little or no
host inﬂammatory response (63). Furthermore, most parasitic
diseases induce T-helper type 2 cytokine-secreting immune
responses, mediated by antibody production and eosinophils.
While such responses may be augmented by restoration of
appropriate T-helper cell function during ART, the resulting
effects on acute inﬂammatory processes are perhaps less likely
to be clinically apparent compared to those resulting from
augmentation of type 1 immune responses. Other reasons for
the lack of reported cases of IRD associated with parasitic
infections may include lack of awareness of health care
personnel or lack of facilities in resource-limited settings to
establish diagnoses. However, as clinical awareness of the
spectrum of IRD increases and experience with ART grows
in resource-limited countries, cases may be recognized more
frequently.
 
Leishmaniasis
 
Visceral disease (VL) is the clinical form of leishmaniasis
that has the most substantial geographical overlap with HIV
and typically occurs as an opportunistic infection among
HIV-infected individuals with CD4 cell counts < 200 cells/
 
µ
 
L (64). This overlap is predominantly in southern Europe
and the horn of Africa but expansion of the HIV epidemic
in India is also likely to result in an increasing number of
co-infected individuals there. In both HIV-infected and
non-infected patients, large numbers of parasites multiply
within phagocytic mononuclear cells and induce a type 2
cytokine response and hypergammaglobulinaemia (65). T cell
proliferation  and IFN-
 
γ
 
  production on stimulation with
leishmania antigen 
 
in vitro
 
 are typically deﬁcient (66).
Many patients with VL have received ART in southern
Europe (67) and yet the number of suspected cases of IRD is
very few. It is notable that all six of the possible cases describe
the unmasking of subclinical infection following initiation
of ART, whereas none of the reports describe clinical deterio-
ration of pre-existing VL (Table  1). Two reports of IRD
associated with 
 
L. infantum
 
 VL in southern France describe
Table 1 Reported cases of immune reconstitution disease associated with parasitic infections
Organism
No. of 
cases Clinical manifestation
Baseline CD4 
cell count/µL
Presentation or 
deterioration Reference
Protozoa
Leishmania infantum 2V isceral leishmaniasis 186, 15 Presentation Berry, 2004 (68)
Leishmania spp. 
(unspeciﬁed)
1V isceral leishmaniasis – Presentation Albrecht, 1998 (69)
3V isceral leishmaniasis 94, 39, 30 Presentation Jimenez-Exposito, 1999 (70)
Leishmania braziliensis 1 Cutaneous + mucosal leishmaniasis 38 Presentation Posada-Vergara, 2005 (74)
1 Cutaneous + mucosal leishmaniasis 23 Deterioration Posada-Vergara, 2005 (74)
Leishmania major 1U v eitis 4 Presentation Blanche, 2002 (77)
Leishmania infantum 1P ost kala azar dermal leishmaniasis 35 Presentation Ridolfo, 2000 (76)
Leishmania donovani 
(presumed)
1P ost kala azar dermal leishmaniasis 150 Presentation Gilad, 2001 (75)
Toxoplasma gondii 1 Cerebral toxoplasmosis 83 Presentation Tsambiras, 2005 (86)
1 Cerebral toxoplasmosis – – Jevtovic, 2001 (85)
Helminths
Schistosoma mansoni 1 Eosinophilia 170 Presentation Fernando, 2002 (83)
1 Eosinophilic enteritis 170 Presentation de Silva, 2006 (84)
Strongyloides stercoralis 1F ever, eosinophilia and hepatitis 32 Presentation Kim, 2004 (81)
1 Disseminated strongyloidiasis 135 Presentation Lanzafame, 2005 (82) 
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asymptomatic patients who developed fever and hepato-
splenomegaly due to VL within the ﬁrst 2 weeks of initiating
ART (68). Another report describes a patient who had not
been to a leishmaniasis-endemic area for 8 years and who,
following commencement of ART, soon developed fever and
thrombocytopenia due to VL (69). A further report describes
three patients in Spain who had an excellent virological response
to ART and yet developed fever and hepatosplenomegaly
during the initial months of ART (70). However, an important
study by de la Rosa 
 
et al
 
. suggests that this phenomenon is
uncommon (71). They described a series of 11 patients with
documented untreated subclinical VL who commenced ART;
none developed clinical VL during follow-up (71), suggesting
that the risk of development of VL-associated IRD among
such patients is low.
Two factors are leading to increased overlap of New World
leishmaniasis and HIV infections in South America: a rising
prevalence of leishmaniasis in urban areas as well as expansion
of the HIV epidemic into rural areas where leishmaniasis is
more common. Cutaneous, mucosal and post kala azar
dermal leishmaniasis (PKDL) are associated with an intense
granulomatous response, causing tissue pathology via a CD4
cell-dependent process (72,73). From a mechanistic viewpoint,
one might therefore expect that IRD would be more commonly
associated with tegumentary forms of disease rather than VL.
However, as yet reports of the former are few.
Two cases of IRD associated with cutaneous and mucosal
leishmaniasis have been reported from Brazil (Table 1) (74).
One patient, who had left an area endemic for leishmaniasis
15  years earlier, developed progressive cutaneous papules,
plaques and ulcers and also ulceration of the oronasopharyn-
geal mucosa after initiating ART. The second HIV-infected
patient presented with multiple cutaneous leishmaniasis lesions,
which deteriorated markedly 1 month after starting ART and
which were also accompanied by development of oronaso-
pharyngeal lesions. Diagnoses of disease due to 
 
Leishmania
braziliensis
 
  were  established in both patients and both
responded well to treatment with either amphotericin B or
pentavalent antimony (74).
Two cases of PKDL presenting as IRD have been reported
from Israel (75) and Italy (76). An Ethiopian immigrant to
Israel who had been treated for VL some years earlier developed
the typical cutaneous lesions of PKDL over the face and
torso 2 weeks after initiating ART (75). The diagnosis was
histologically conﬁrmed. The other case was an HIV-infected
patient who was initially treated for VL and then developed
PKDL on her lower limbs 6 months after commencing ART
(76). However, a diagnosis of IRD in this latter case cannot be
strongly justiﬁed and the presentation may simply represent
the normal presentation of PKDL.
A further patient with diffuse cutaneous leishmaniasis in
France treated successfully with amphotericin B developed
severe bilateral granulomatous anterior uveitis 4 months after
starting ART (77). Treatment with liposomal amphotericin
B and interferon-
 
γ
 
 (IFN-
 
γ
 
) failed to control the disease and
one eye had to be enucleated. Histological examination revealed
ﬂorid inﬂammation and the presence of amastigotes. A
further similar case of fulminant ocular leishmaniasis due to
 
Leishmania donovani
 
 during ART has been reported from the
Netherlands (78). Histological examination of the enucleated
eye revealed massive granulomatous inﬁltrates throughout
the eye but the distinction between active infection and IRD
was unclear.
 
Strongyloidiasis
 
The lack of an association between HIV-related immuno-
deﬁciency and risk of disseminated strongyloidiasis has been
intriguing (79). A possible explanation for this is suggested by
data reported by Viney 
 
et al
 
., who demonstrated that progres-
sive HIV-associated CD4 lymphocytopenia was associated
with diminishing likelihood of larval maturation within the
gut. Decreased larval maturation would diminish the risk
of autoinfection – a process required in the development of
hyperinfection (80). However, two cases of possible IRD
involving disseminated strongyloidiasis have now been reported,
representing a new and unexpected interaction (81,82). Both
were in immigrants from low-income to high-income countries
and presented within the ﬁrst weeks of ART. The ﬁrst case
developed fever, eosinophilia and hepatitis (81); the second
patient presented with gastrointestinal symptoms and pruritis,
and investigations revealed pulmonary radiographic inﬁltrates
and eosinophilia (82). Numerous larvae of 
 
Strongyloides
stercoralis
 
 were found in stool specimens from both patients
and both responded well to antihelminthic treatment. Both
cases were temporally related to the commencement of ART.
It is not clear whether these cases arose due to the triggering
of immune responses to pre-existing disseminated infection
in these patients or whether immune recovery facilitated
dissemination of strongyloidiasis. Of note, the ﬁrst case had
recently received corticosteroids as a component of treatment
for cerebral toxoplasmosis and this would have served as
a potent stimulus for dissemination of the strongyloides
infection prior to starting ART.
 
Schistosomiasis
 
Two cases of schistosomiasis-associated IRD have been reported
(Table 1) (83,84). The ﬁrst report describes an African immi-
grant to the UK who was found to be HIV-infected and to
have hepatosplenomegaly. The baseline eosinophil count was
normal but this increased 1 month after initiating ART and
peaked at 1·5 
 
×
 
 10
 
9
 
 cells/L after 4 months of treatment. The
hepatosplenomegaly was proven by biopsy to be due to 
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Schistosoma mansoni
 
 infection and the patient was treated
with praziquantel, leading to a reduction in eosinophil count.
No clinical manifestations accompanied the eosinophilia and
so this might be better termed an immune reconstitution
‘phenomenon’ rather than ‘disease’. The second report described
a South African man who emigrated to the UK and 14 years
later commenced ART (84). Treatment was stopped and
reinitiated on ﬁve occasions due to development of vomiting,
diarrhoea and abdominal pain. Symptoms developed within
the ﬁrst few weeks of treatment on each occasion. Colonos-
copy revealed patchy inﬂammation of the large bowel and
mucosal biopsies showed ﬂorid eosinophilic granulomatous
inﬂammation associated with both viable and dead eggs of
 
S. mansoni.
 
 No comment was made on whether the episodes
were associated with peripheral blood eosinophilia. Subsequent
treatment for schistosomiasis led to resolution of symptoms.
Disease associated with schistosomiasis is mediated by
eosinophilic granulomatous inﬂammation associated with ova.
As with the cases of strongyloides-associated IRD, enhance-
ment of T helper type 2 responses may have exacerbated
eosinophilic inﬂammation in both of these cases. If schistosoma
eggs antigens were responsible for triggering the immune-
mediated inﬂammation within the intestinal wall in the case
described by de Silva 
 
et al
 
. (84), it is intriguing that symptoms
were resolved following praziquantel treatment, which would
not have affected the existing egg antigen burden within the
intestinal mucosa.
Large numbers of patients have received ART in east Africa
where the prevalence of schistosomiasis is high and yet no
reports of schistosomiasis-associated IRD have emerged
from the region. Awareness of this potential complication of
ART may lead to recognition of further cases.
 
Other parasites
 
Just two cases of suspected IRD associated with toxoplasma
encephalitis have been reported in published literature. In
one case no clinical details were given (85). In the other, an
HIV-infected patient with a nadir CD4 cell count of 83 cells/
 
µ
 
L presented with a focal seizure after 3 weeks of ART (86).
This was diagnosed as cerebral toxoplasmosis on the basis
of positive serology, multiple ring-enhancing intracerebral
lesions on a magnetic resonance imaging scan and a positive
response to treatment for toxoplasmosis. Toxoplasmosis is a
common end-stage opportunistic infection in industrialized
countries for which ART is often initiated fairly early. The
fact that more cases have not been reported casts some doubt
on whether this infection may be associated with IRD.
There are no reports in the literature of IRD associated
with helminthic or protozoal infections other than those
described above. However, an important question is whether
malaria may be associated with IRD. Although large
numbers of individuals have received ART in sub-Saharan
African countries where 
 
Plasmodium falciparum
 
 malaria is
hyperendemic, no cases of malaria-associated IRD have been
reported. The likeliest manifestation, however, might be very
non-speciﬁc such as development of fever; it seems unlikely
that severe manifestations would arise.
 
CONCLUSIONS
 
IRD associated with infections has emerged as an important
cause of morbidity complicating the initial months of ART.
As access to ART is scaled up in many low-income countries,
the extent to which IRD will contribute to morbidity and
mortality in treatment programmes has yet to be determined.
However, as patients typically present to ART services with
marked lymphocytopenia and frequent co-infections, IRD
is likely to be common. Most IRD results from dysregulated
augmentation of cell-mediated immune responses to myco-
bacterial, chronic viral and invasive fungal infections. How-
ever, the spectrum of infections recognized to be associated
with IRD now encompasses a number of parasitic diseases,
including leishmaniasis (visceral, cutaneous, mucosal and
PKDL), schistosomiasis and strongyloidiasis. No studies have
yet examined the mechanisms of IRD associated with helminth
infections, but these may be due to augmentation of appro-
priate type 2 immune responses. More research is needed to
increase our understanding of these emerging phenomena.
 
ACKNOWLEDGEMENTS
 
SDL and RJW are both funded by the Wellcome Trust, UK
with grant numbers 074641/Z/04/Z (SDL) and 072070 (RJW).
 
REFERENCES
 
1 Egger M, May M, Chene G 
 
et al.
 
 Prognosis of HIV-1-infected
patients starting highly active antiretroviral therapy: a
collaborative analysis of prospective studies. 
 
Lancet
 
 2002; 
 
360
 
:
119–129.
2P alella FJ Jr, Delaney KM, Moorman AC 
 
et al.
 
  Declining
morbidity and mortality among patients with advanced human
immunodeﬁciency virus infection. HIV Outpatient Study
Investigators. 
 
N Engl J Med
 
 1998; 
 
338
 
: 853–860.
3 Mocroft A, Vella S, Benﬁeld TL 
 
et al.
 
 Changing patterns of
mortality across Europe in patients infected with HIV-1.
EuroSIDA Study Group. 
 
Lancet
 
 1998; 
 
352
 
: 1725–1730.
4A utran B, Carcelain G, Li TS 
 
et al.
 
 Positive effects of combined
antiretroviral therapy on CD4+ T cell homeostasis and function
in advanced HIV disease. 
 
Science
 
 1997; 
 
277
 
: 112–116.
5 Carcelain G, Debre P & Autran B. Reconstitution of CD4+ T
lymphocytes in HIV-infected individuals following antiretroviral
therapy. 
 
Curr Opin Immunol
 
 2001; 
 
13
 
: 483–488.
6 Lederman MM. Immune restoration and CD4+ T-cell function
with antiretroviral therapies. 
 
AIDS
 
 2001; 
 
15
 
 (Suppl. 2): S11–
S15. 
© 2006 The Authors 
 
631
 
Journal compilation © 2006 Blackwell Publishing Ltd, 
 
Parasite Immunology
 
, 
 
28
 
, 625–633
 
Volume 28, Number 11, November 2006 Immune reconstitution disease
 
7 Kirk O, Reiss P, Uberti-Foppa C 
 
et al.
 
  Safe interruption of
maintenance therapy against previous infection with four
common HIV-associated opportunistic pathogens during potent
antiretroviral therapy. 
 
Ann Intern Med
 
 2002; 
 
137
 
: 239–250.
8 Shelburne SA III & Hamill RJ. The immune reconstitution
inﬂammatory syndrome. 
 
AIDS Rev
 
 2003; 
 
5
 
: 67–79.
9F r ench MA, Price P & Stone SF. Immune restoration disease
after antiretroviral therapy. 
 
AIDS
 
 2004; 
 
18
 
: 1615–1627.
10 Lawn SD, Bekker LG & Miller RF. Immune reconstitution
disease associated with mycobacterial infections in HIV-infected
individuals receiving antiretrovirals. 
 
Lancet Infect Dis
 
 2005; 
 
5
 
:
361–373.
11 Cheng VC, Yuen KY, Wong SS 
 
et al.
 
 Immunorestitution diseases
in patients not infected with HIV. 
 
Eur J Clin Microbiol Infect
Dis
 
 2001; 
 
20
 
: 402–406.
12 WHO/UNAIDS. Progress of global access to HIV antiretroviral
therapy. An update on ‘3 by 5’. June 2005. http://www.who.
International/hiv/pub/progressreports/3by5%20Progress%20
Report_E_light.pdf. Accessed 19.10.05. 2005.
13 Lawn SD, Myer L, Orrell C 
 
et al.
 
 Early mortality among adults
accessing a community-based antiretroviral service in South
Africa: implications for programme design. 
 
AIDS
 
  2005; 
 
19
 
:
2141–2148.
14 Colebunders R, Ronald A, Katabira E 
 
et al.
 
  Rolling out
antiretrovirals in Africa: there are still challenges ahead. 
 
Clin
Infect Dis
 
 2005; 
 
41
 
: 386–389.
15 Lawn SD, Bekker LG, Myer L 
 
et al.
 
 Cryptococcocal immune
reconstitution disease: a major cause of early mortality in a
South African antiretroviral programme. 
 
AIDS
 
 2005; 
 
19
 
: 2050–
2052.
16 Evans TG, Bonnez W, Soucier HR 
 
et al.
 
 Highly active anti-
retroviral therapy results in a decrease in CD8+ T cell activation
and preferential reconstitution of the peripheral CD4+ T cell
population with memory rather than naive cells. 
 
Antiviral Res
 
1998; 39: 163–173.
17 Chavan SJ, Tamma SL, Kaplan M et al. Reduction in T cell
apoptosis in patients with HIV disease following antiretroviral
therapy. Clin Immunol 1999; 93: 24–33.
18 Le Moing V, Thiebaut R, Chene G et al. Predictors of long-term
increase in CD4 (+) cell counts in human immunodeﬁciency
virus-infected patients receiving a protease inhibitor-containing
antiretroviral regimen. J Infect Dis 2002; 185: 471–480.
19 Bennett KK, DeGruttola VG, Marschner IC et al. Baseline
predictors of CD4 T-lymphocyte recovery with combination
antiretroviral therapy. J Acquir Immune Deﬁc Syndr 2002; 31:
20–26.
20 Renaud M, Katlama C, Mallet A et al. Determinants of paradoxical
CD4 cell reconstitution after protease inhibitor-containing
antiretroviral regimen. AIDS 1999; 13: 669–676.
21 Lawn SD, Myer L, Bekker LG et al. CD4 cell count recovery
among HIV-infected patients with very advanced immunodeﬁ-
ciency commencing antiretroviral treatment in sub-Saharan Africa.
BMC Infect Dis 2006; 6: 59.
22 Landay AL, Bettendorf D, Chan E et al. Evidence of immune
reconstitution in antiretroviral drug-experienced patients with
advanced HIV disease. AIDS Res Hum Retroviruses 2002; 18:
95–102.
23 Valdez H, Smith KY, Landay A et al. Response to immuniza-
tion with recall and neoantigens after prolonged administration
of an HIV-1 protease inhibitor-containing regimen. ACTG 375
team. AIDS Clinical Trials Group. AIDS 2000; 14: 11–21.
24 Wendland T, Furrer H, Vernazza PL et al. HAART in HIV-
infected patients: restoration of antigen-speciﬁc CD4 T-cell
responses  in vitro  is correlated with CD4 memory T-cell
reconstitution, whereas improvement in delayed type hyper-
sensitivity is related to a decrease in viraemia. AIDS 1999; 13:
1857–1862.
25 Hardy GA, Imami N, Sullivan AK et al.  Reconstitution of
CD4+ T cell responses in HIV-1 infected individuals initiating
highly active antiretroviral therapy (HAART) is associated with
renewed interleukin-2 production and responsiveness. Clin Exp
Immunol 2003; 134: 98–106.
26 Imami N, Antonopoulos C, Hardy GA et al. Assessment of
type 1 and type 2 cytokines in HIV type 1-infected individuals:
impact of highly active antiretroviral therapy. AIDS Res Hum
Retroviruses 1999; 15: 1499–1508.
27 Gorochov G, Neumann AU, Kereveur A et al. Perturbation of
CD4+ and CD8+ T-cell repertoires during progression to AIDS
and regulation of the CD4+ repertoire during antiviral therapy.
Nat Med 1998; 4: 215–221.
28 Worrell S, Deayton J, Hayes P et al. Molecular correlates in
AIDS patients following antiretroviral therapy: diversiﬁed T-cell
receptor repertoires and in vivo control of cytomegalovirus
replication. HIV Med 2001; 2: 11–19.
29 French MA, Mallal SA & Dawkins RL. Zidovudine-induced
restoration of cell-mediated immunity to mycobacteria in
immunodeﬁcient HIV-infected patients. AIDS 1992;  6: 1293–
1297.
30 Crowe SM, Vardaxis NJ, Kent SJ et al.  HIV infection of
monocyte-derived macrophages in vitro reduces phagocytosis of
Candida albicans. J Leukoc Biol 1994; 56: 318–327.
31 Gazzinelli RT, Bala S, Stevens R et al. HIV infection suppresses
type 1 lymphokine and IL-12 responses to Toxoplasma gondii but
fails to inhibit the synthesis of other parasite-induced monokines.
J Immunol 1995; 155: 1565–1574.
32 Imperiali FG, Zaninoni A, La Maestra L et al.  Increased
Mycobacterium tuberculosis  growth in HIV-1-infected human
macrophages: role of tumour necrosis factor-alpha. Clin Exp
Immunol 2001; 123: 435–442.
33 Baldwin GC, Fleischmann J, Chung Y et al. Human immuno-
deﬁciency virus causes mononuclear phagocyte dysfunction.
Proc Natl Acad Sci USA 1990; 87: 3933–3937.
34 Smith PD, Ohura K, Masur H et al. Monocyte function in the
acquired immune deﬁciency syndrome. Defective chemotaxis.
J Clin Invest 1984; 74: 2121–2128.
35 Finke JS, Shodell M, Shah K et al. Dendritic cell numbers in the
blood of HIV-1 infected patients before and after changes in
antiretroviral therapy. J Clin Immunol 2004; 24: 647–652.
36 Chehimi J, Campbell DE, Azzoni L et al. Persistent decreases in
blood plasmacytoid dendritic cell number and function despite
effective highly active antiretroviral therapy and increased blood
myeloid dendritic cells in HIV-infected individuals. J Immunol
2002; 168: 4796–4801.
37 Barron MA, Blyveis N, Palmer BE et al. Inﬂuence of plasma
viremia on defects in number and immunophenotype of blood
dendritic cell subsets in human immunodeﬁciency virus 1-
infected individuals. J Infect Dis 2003; 187: 26–37.
38 Douglas SD, Durako SJ, Tustin NB et al. Natural killer cell
enumeration and function in HIV-infected and high-risk
uninfected adolescents. AIDS Res Hum Retroviruses 2001; 17:
543–552.
39 Parato KG, Kumar A, Badley AD et al. Normalization of
natural killer cell function and phenotype with effective anti-
HIV therapy and the role of IL-10. AIDS 2002; 16: 1251–1256.632 © 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd, Parasite Immunology, 28, 625–633
S. D. Lawn & R. J. Wilkinson Parasite Immunology
40 Vogler MA, Teppler H, Gelman R et al. Daily low-dose subcu-
taneous interleukin-2 added to single- or dual-nucleoside therapy
in HIV infection does not protect against CD4+ T-cell decline or
improve other indices of immune function: results of a randomized
controlled clinical trial (ACTG 248). J Acquir Immune Deﬁc
Syndr 2004; 36: 576–587.
41 Azzoni L, Papasavvas E, Chehimi J et al. Sustained impairment
of IFN-gamma secretion in suppressed HIV-infected patients
despite mature NK cell recovery: evidence for a defective recon-
stitution of innate immunity. J Immunol 2002; 168: 5764–5770.
42 Oxenius A, Price DA, Dawson SJ et al. Residual HIV-speciﬁc
CD4 and CD8 T cell frequencies after prolonged antiretroviral
therapy reﬂect pretreatment plasma virus load. AIDS 2002; 16:
2317–2322.
43 Kharbanda M, Than S, Chitnis V et al. Patterns of CD8 T cell
clonal dominance in response to change in antiretroviral therapy
in HIV-infected children. AIDS 2000; 14: 2229–2238.
44 Carbonneil C, Donkova-Petrini V, Aouba A et al.  Defective
dendritic cell function in HIV-infected patients receiving effec-
tive highly active antiretroviral therapy: neutralization of IL-10
production and depletion of CD4+CD25+ T cells restore high
levels of HIV-speciﬁc CD4+ T cell responses induced by dendritic
cells generated in the presence of IFN-alpha. J Immunol 2004;
172: 7832–7840.
45 Andersson J, Boasso A, Nilsson J et al. The prevalence of
regulatory T cells in lymphoid tissue is correlated with viral load
in HIV-infected patients. J Immunol 2005; 174: 3143–3147.
46 De Milito A. B lymphocyte dysfunctions in HIV infection. Curr
HIV Res 2004; 2: 11–21.
47 Grau I, Pallares R, Tubau F et al. Epidemiologic changes in
bacteremic pneumococcal disease in patients with human
immunodeﬁciency virus in the era of highly active antiretroviral
therapy. Arch Intern Med 2005; 165: 1533–1540.
48 Yamanaka H, Teruya K, Tanaka M et al. Efﬁcacy and immuno-
logic responses to inﬂuenza vaccine in HIV-1-infected patients.
J Acquir Immune Deﬁc Syndr 2005; 39: 167–173.
49 Rimland D & Guest JL. Response to hepatitis A vaccine in HIV
patients in the HAART era. AIDS 2005; 19: 1702–1704.
50 Popovic M, Tenner-Racz K, Pelser C et al. Persistence of HIV-
1 structural proteins and glycoproteins in lymph nodes of
patients under highly active antiretroviral therapy. Proc Natl
Acad Sci USA 2005; 102: 14807–14812.
51 Narita M, Ashkin D, Hollender ES et al. Paradoxical worsening
of tuberculosis following antiretroviral therapy in patients with
AIDS. Am J Respir Crit Care Med 1998; 158: 157–161.
52 Olalla J, Pulido F, Rubio R et al. Paradoxical responses in a
cohort of HIV-1-infected patients with mycobacterial disease.
Int J Tuberc Lung Dis 2002; 6: 71–75.
53 Bourgarit A, Carcelain G, Martinez V et al. Explosion of tuberculin-
speciﬁc Th1-responses induces immune restoration syndrome
in tuberculosis and HIV co-infected patients. AIDS 2006; 20:
F1–F7.
54 Foudraine NA, Hovenkamp E, Notermans DW et al. Immuno-
pathology as a result of highly active antiretroviral therapy in
HIV-1-infected patients. AIDS 1999; 13: 177–184.
55 Havlir DV, Schrier RD, Torriani FJ et al.  Effect of potent
antiretroviral therapy on immune responses to Mycobacterium
avium in human immunodeﬁciency virus-infected subjects.
J Infect Dis 2000; 182: 1658–1663.
56 Lawn SD & Macallan DC. Hypercalcemia: a manifestation of
immune reconstitution complicating tuberculosis in an HIV-
infected person. Clin Infect Dis 2004; 38: 154–155.
57 Jenny-Avital ER & Abadi M. Immune reconstitution crypto-
coccosis after initiation of successful highly active antiretroviral
therapy. Clin Infect Dis 2002; 35: e128–e133.
58 Mutimer HP, Akatsuka Y, Manley T et al. Association between
immune recovery uveitis and a diverse intraocular cytomegalovirus-
speciﬁc cytotoxic T cell response. J Infect Dis 2002; 186: 701–
705.
59 Miralles P, Berenguer J, Lacruz C et al. Inﬂammatory reactions
in progressive multifocal leukoencephalopathy after highly active
antiretroviral therapy. AIDS 2001; 15: 1900–1902.
60 Martinez E, Gatell J, Moran Y et al. High incidence of herpes
zoster in patients with AIDS soon after therapy with protease
inhibitors. Clin Infect Dis 1998; 27: 1510–1513.
61 Zylberberg H, Pialoux G, Carnot F et al. Rapidly evolving
hepatitis C virus-related cirrhosis in a human immunodeﬁciency
virus-infected patient receiving triple antiretroviral therapy.
Clin Infect Dis 1998; 27: 1255–1258.
62 Price P, Morahan G, Huang D et al.  Polymorphisms in
cytokine genes deﬁne subpopulations of HIV-1 patients who
experienced immune restoration diseases. AIDS  2002;  16:
2043–2047.
63 Gupta S. Parasite immune escape: new views into host–parasite
interactions. Curr Opin Microbiol 2005; 8: 428–433.
64 Olivier M, Badaro R, Medrano FJ et al. The pathogenesis of
Leishmania/HIV co-infection: cellular and immunological
mechanisms. Ann Trop Med Parasitol 2003; 97 (Suppl. 1) 79–98.
65 Zwingenberger K, Harms G, Pedrosa C et al. Determinants of
the immune response in visceral leishmaniasis: evidence for pre-
dominance of endogenous interleukin 4 over interferon-gamma
production. Clin Immunol Immunopathol 1990; 57: 242–249.
66 Carvalho EM, Bacellar O, Brownell C et al.  Restoration of
IFN-gamma production and lymphocyte proliferation in visceral
leishmaniasis. J Immunol 1994; 152: 5949–5956.
67 Lopez-Velez R. The impact of highly active antiretroviral
therapy (HAART) on visceral leishmaniasis in Spanish patients
who are co-infected with HIV. Ann Trop Med Parasitol 2003; 97
(Suppl. 1): 143–147.
68 Berry A, Abraham B, Dereure J et al. Two case reports of symp-
tomatic visceral leishmaniasis in AIDS patients concomitant
with immune reconstitution due to antiretroviral therapy. Scand
J Infect Dis 2004; 36: 225–227.
69 Albrecht H. Leishmaniosis – new perspectives on an under-
appreciated opportunistic infection. AIDS 1998; 12: 2225–2226.
70 Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P et al. Visceral
leishmaniasis in HIV-infected patients with non-detectable HIV-
1 viral load after highly active antiretroviral therapy. AIDS
1999; 13: 152–153.
71 de la RR, Pineda JA, Delgado J et al. Inﬂuence of highly active
antiretroviral therapy on the outcome of subclinical visceral
leishmaniasis in human immunodeﬁciency virus-infected patients.
Clin Infect Dis 2001; 32: 633–635.
72 Soong L, Chang CH, Sun J et al. Role of CD4+ T cells in
pathogenesis associated with Leishmania amazonensis infection.
J Immunol 1997; 158: 5374–5383.
73 Terabe M, Kuramochi T, Ito M et al.  CD4 (+) cells are
indispensable for ulcer development in murine cutaneous
leishmaniasis. Infect Immun 2000; 68: 4574–4577.
74 Posada-Vergara MP, Lindoso JA, Tolezano JE et al. Tegumentary
leishmaniasis as a manifestation of immune reconstitution
inﬂammatory syndrome in 2 patients with AIDS. J Infect Dis
2005; 192: 1819–1822.
75 Gilad J, Borer A, Hallel-Halevy D et al. Post-kala-azar dermal© 2006 The Authors  633
Journal compilation © 2006 Blackwell Publishing Ltd, Parasite Immunology, 28, 625–633
Volume 28, Number 11, November 2006 Immune reconstitution disease
leishmaniasis manifesting after initiation of highly active anti-
retroviral therapy in a patient with human immunodeﬁciency
virus infection. Isr Med Assoc J 2001; 3: 451–452.
76 Ridolfo AL, Gervasoni C, Antinori S et al. Post-kala-azar
dermal leishmaniasis during highly active antiretroviral therapy
in an AIDS patient infected with Leishmania infantum. J Infect
2000; 40: 199–202.
77 Blanche P, Gombert B, Rivoal O et al. Uveitis due to Leishmania
major  as part of HAART–induced immune restitution
syndrome in a patient with AIDS. Clin Infect Dis  2002;  34:
1279–1280.
78 Meenken C, van Agtmael MA, Ten Kate RW et al. Fulminant
ocular leishmaniasis in an HIV-1-positive patient. AIDS 2004;
18: 1485–1486.
79 Lucas SB. Missing infections in AIDS. Trans R Soc Trop Med
Hyg 1990; 84 (Suppl. 1): 34–38.
80 Viney ME, Brown M, Omoding NE et al.  Why does HIV
infection not lead to disseminated strongyloidiasis? J Infect Dis
2004; 190: 2175–2180.
81 Kim AC & Lupatkin HC. Strongyloides stercoralis infection as
a manifestation of immune restoration syndrome. Clin Infect Dis
2004; 39: 439–440.
82 Lanzafame M, Faggian F, Lattuada E et al. Strongyloidiasis in
an HIV-1-infected patient after highly active antiretroviral therapy-
induced immune restoration. J Infect Dis 2005; 191: 1027.
83 Fernando R & Miller R. Immune reconstitution eosinophilia
due to schistosomiasis. Sex Transm Infect 2002; 78: 76.
84 de Silva S, Walsh J & Brown M. Symptomatic Schistosoma
mansoni infection as an immune restoration phenomenon in a
patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42:
303–304.
85 Jevtovic DJ, Salemovic D, Ranin J et al. The prevalence and risk
of immune restoration disease in HIV-infected patients treated
with highly active antiretroviral therapy. HIV Med 2005; 6: 140–
143.
86 Tsambiras PE, Larkin JA & Houston SH. Case report. Toxo-
plasma encephalitis after initiation of HAART. AIDS Read
2001; 11: 608–606.